GO
Loading...

Cramer: Buy Bristol-Myers, Pfizer Stock

Most investors had long stayed away from pharmaceutical stocks because the major drug companies were losing patent protection on their largest products. Although the “patent expiration apocalypse” continues, many investors are now buying big pharma because they think the worst is over.

Cramer sees a major opportunity here and after recommending Merck on Monday’s “Mad Money,” he’s getting behind Bristol-Myers and Pfizer , as well.

Bristol-Myers and Pfizer have been working on a groundbreaking drug called Eliquis, an oral anticoagulant that prevents stroke in patients with atrial fibrillation, which is the most common form of cardiac arrhythmia or irregular heartbeat. It appears to be highly effective and could be a needle mover, too. If approved in March, the drug could generate more than $5 billion in peak sales with the money being divided between the two companies.

Cramer said Eliquis is just one reason to own Bristol-Myers and Pfizer, though. Both stocks sports juicy dividend yields of 4.3 and 4 percent respectively.

Symbol
Price
 
Change
%Change
BMY
---
PFE
---

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Symbol
Price
 
Change
%Change
BMY
---
MRK
---
PFE
---

Featured

Contact Mad Money

  • Showtimes

    U.S.
    Monday - Friday 6p ET
    Australia
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.